NCT06642558View on ClinicalTrials.gov

Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

522

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

February 28, 2027

Conditions
Respiratory Syncytial Virus (RSV)
Interventions
BIOLOGICAL

Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose)

0.25 mL per dose.

BIOLOGICAL

Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose)

0.5 mL per dose

BIOLOGICAL

Placebo (Saline solution)

0.5 mL per dose

Trial Locations (1)

476000

Liangyuan District Center for Disease Prevention and Control, Shangqiu

Sponsors
All Listed Sponsors
collaborator

Henan Center for Disease Control and Prevention

OTHER_GOV

lead

MAXVAX Biotechnology Limited Liability Company

INDUSTRY

NCT06642558 - Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above | Biotech Hunter | Biotech Hunter